As Shareholder Vote Looms, Genesis Provides New Details on ssRNAi Subsidiary
October 15, 2009
As Shareholder Vote Looms, Genesis Provides New Details on ssRNAi Subsidiary
According to Genesis, the primary investor in the subsidiary is Japan's MediBic Group, which is primarily a pharmacogenomics firm but has made investments in RNAi drug shop Intradigm.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genesis Research and Development Proposes Stock Purchase Plan to Fund ssRNAi Subsidiary
February 18, 2010 / Gene Silencing News - Genesis Shareholders OK Spinout of Company ssRNAi Assets into New Firm
October 29, 2009 / Gene Silencing News - Genesis Research and Development Halts Operations Amid Cash Shortfall
May 6, 2010 / Gene Silencing News - Genesis R&D Inks Deal to Sell 7.4M Shares of Stock
June 17, 2010 / Gene Silencing News - Genesis R&D Finalizes Terms of Investment Deal for New Subsidiary
August 6, 2009 / Gene Silencing News